Overview

A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma

Status:
Terminated
Trial end date:
2013-11-05
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the response of subjects with recurrent glioblastoma to continuous therapy of PLX3397.
Phase:
Phase 2
Details
Lead Sponsor:
Daiichi Sankyo, Inc.
Plexxikon
Collaborator:
Plexxikon